AstraZeneca Pharma India Limited (BOM: 506820)

India flag India · Delayed Price · Currency is INR
6,770.60
-362.50 (-5.08%)
At close: Nov 14, 2024
46.15%
Market Cap 169.27B
Revenue (ttm) 14.85B
Net Income (ttm) 819.20M
Shares Out 25.00M
EPS (ttm) 32.77
PE Ratio 206.58
Forward PE n/a
Dividend 24.00 (0.35%)
Ex-Dividend Date Jul 5, 2024
Volume 2,973
Open 7,180.00
Previous Close 7,133.10
Day's Range 6,672.60 - 7,180.00
52-Week Range 4,050.15 - 8,139.85
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra bran... [Read more]

Industry Pharmaceutical Preparations
Founded 1979
Employees 940
Stock Exchange Bombay Stock Exchange
Ticker Symbol 506820
Full Company Profile

Financial Performance

In 2023, AstraZeneca Pharma India's revenue was 12.96 billion, an increase of 29.17% compared to the previous year's 10.03 billion. Earnings were 1.62 billion, an increase of 62.66%.

Financial Statements

News

AstraZeneca Pharma India shares surge over 8% amid focus on cancer projects and clinical trials

Shares of AstraZeneca Pharma India Ltd. witnessed a sharp rise of 8.26% on October 7, trading at ₹8,051. The stock opened at ₹7,440, surged to an intraday high of ₹8,129.95, and has been moving positi...

5 weeks ago - Business Upturn

AstraZeneca Pharma surges over 7%, hits 52-week high during early trades

AstraZeneca Pharma India Ltd witnessed a significant surge in its stock price, rising over 7% to ₹7,697 as of 10:11 AM today. The stock opened at ₹7,150, reached a high of ₹7,743, and recorded a low o...

6 weeks ago - Business Upturn

AstraZeneca gets nod to launch cancer drug

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resecta...

7 weeks ago - The Times of India